National Cancer Institute (NCI): all 3,554 studies

Page 13 of 36. Open to participants first (334), then studies with results posted, then the rest; newest registration first within each.

• Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by SurgeryCompletedNCT00770809Phase 3Results posted
• Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone LumpectomyCompletedNCT00769379Phase 3Results posted
• Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or AdenomaCompletedNCT00754494Phase 2Results posted
• Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the OvaryCompletedNCT00748657Phase 2Results posted
• Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00742625Phase 1/2Results posted
• Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung CancerTerminatedNCT00738881Phase 3Results posted
• Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic CancerCompletedNCT00735917Phase 2Results posted
• Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00731731Phase 1/2Results posted
• Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial CancerCompletedNCT00729586Phase 2Results posted
• Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine TherapyCompletedNCT00729157Phase 2Results posted
• Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00723255Phase 2Results posted
• Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00720109Phase 2/3Results posted
• Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00719901Phase 1/2Results posted
• Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic CancerTerminatedNCT00718809Phase 2Results posted
• Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma PatientsTerminatedNCT00706992Phase 2Results posted
• Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell LymphomaCompletedNCT00703664Phase 2Results posted
• Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host DiseaseCompletedNCT00702689Phase 2Results posted
• Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast CancerCompletedNCT00699491Phase 1/2Results posted
• Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerCompletedNCT00698815Phase 2Results posted
• Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination ChemotherapyCompletedNCT00693992Phase 3Results posted
• Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney CancerTerminatedNCT00684996Phase 1/2Results posted
• Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast CancerCompletedNCT00684983Phase 2Results posted
• Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard TherapyCompletedNCT00679354Phase 2Results posted
• Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic CancerTerminatedNCT00670748Phase 2Results posted
• Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00669019Phase 2Results posted
• Tandutinib Plus Bevacizumab to Treat Recurrent Brain TumorsCompletedNCT00667394Phase 2Results posted
• R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate CancerCompletedNCT00666666Phase 2Results posted
• Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid LeukemiaCompletedNCT00666588Phase 2Results posted
• Green Tea Extract in Treating Patients With Nonmetastatic Bladder CancerCompletedNCT00666562Phase 2Results posted
• Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat MelanomaCompletedNCT00665470Phase 2Results posted
• AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00659360Phase 2Results posted
• Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaActive, not recruitingNCT00658814Phase 2Results posted
• Montelukast to Treat Bronchiolitis ObliteransCompletedNCT00656058Phase 2Results posted
• Viral Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00651157Phase 2Results posted
• Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple MyelomaActive, not recruitingNCT00644228Phase 3Results posted
• Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma MultiformeCompletedNCT00641706Phase 2Results posted
• Curcumin in Treating Patients With Familial Adenomatous PolyposisCompletedNCT00641147Phase 2Results posted
• IMC-A12 in Treating Patients With Advanced Liver CancerCompletedNCT00639509Phase 2Results posted
• AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination ChemotherapyCompletedNCT00638937Phase 2Results posted
• Satraplatin and Prednisone to Treat Prostate CancerCompletedNCT00634647Phase 2Results posted
• Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00634244Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid CancerCompletedNCT00625846Phase 2Results posted
• S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00617708Phase 1/2Results posted
• Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced MelanomaTerminatedNCT00612222Phase 2Results posted
• Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced MelanomaTerminatedNCT00610311Phase 2Results posted
• Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction CancerCompletedNCT00607594Phase 2Results posted
• Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver CancerCompletedNCT00604721Phase 2Results posted
• Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid LeukemiaCompletedNCT00602771Phase 2Results posted
• Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT00602641Phase 3Results posted
• Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic LeukemiaCompletedNCT00602459Phase 2Results posted
• F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast CancerCompletedNCT00602043Phase 2Results posted
• Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast CancerCompletedNCT00601900Phase 3Results posted
• Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate CancerCompletedNCT00589472Phase 2Results posted
• Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced StageCompletedNCT00589290Phase 2Results posted
• Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid LeukemiaCompletedNCT00588809Phase 2Results posted
• Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT00588770Phase 3Results posted
• Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic CancerCompletedNCT00577889Phase 2Results posted
• Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast CancerCompletedNCT00572728Phase 2Results posted
• Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine TumorActive, not recruitingNCT00569127Phase 3Results posted
• Phase II Study of Vandetanib in Individuals With Kidney CancerCompletedNCT00566995Phase 2Results posted
• Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT00565851Phase 3Results posted
• Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic LeukemiaCompletedNCT00563290Phase 2Results posted
• Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive IodineCompletedNCT00559949Phase 2Results posted
• Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By SurgeryCompletedNCT00559507Phase 2Results posted
• FDG and FMISO PET Hypoxia Evaluation in Cervical CancerCompletedNCT00559377Phase 2Results posted
• Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In SituCompletedNCT00555152Not applicableResults posted
• Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00553644Phase 2Results posted
• Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By SurgeryCompletedNCT00553332Phase 2Results posted
• Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal CancerCompletedNCT00551421Phase 1/2Results posted
• Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum CancerCompletedNCT00551070Phase 2Results posted
• Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCompletedNCT00540722Phase 2Results posted
• AZD0530 in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT00528645Phase 2Results posted
• Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyTerminatedNCT00527124Phase 2Results posted
• Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With DexamethasoneTerminatedNCT00522392Phase 3Results posted
• Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid TumorsCompletedNCT00521144Phase 1/2Results posted
• Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEUTerminatedNCT00520975Phase 3Results posted
• Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune SystemCompletedNCT00520130Phase 1/2Results posted
• Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing SarcomaCompletedNCT00516295Phase 2Results posted
• Sunitinib in Treating Patients With Relapsed Multiple MyelomaCompletedNCT00514137Phase 2Results posted
• Vandetanib to Treat Children and Adolescents With Medullary Thyroid CancerCompletedNCT00514046Phase 1/2Results posted
• Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic MelanomaCompletedNCT00513604Phase 2Results posted
• Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00513435Phase 2Results posted
• Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by SurgeryCompletedNCT00513292Phase 3Results posted
• AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone TherapyCompletedNCT00513071Phase 2Results posted
• Pazopanib in Treating Patients With Recurrent or Metastatic Breast CancerCompletedNCT00509587Phase 2Results posted
• Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered LymphocytesTerminatedNCT00509496Phase 2Results posted
• Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered LymphocytesCompletedNCT00509288Phase 2Results posted
• Aflibercept in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00509249Phase 2Results posted
• Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00507767Phase 2Results posted
• Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT00504153Phase 2Results posted
• Sunitinib in Treating Patients With Recurrent Malignant GliomasCompletedNCT00499473Phase 2Results posted
• Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line TherapyTerminatedNCT00499369Phase 3Results posted
• Decitabine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00492401Phase 2Results posted
• Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2Results posted
• Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone TherapyCompletedNCT00486642Phase 2Results posted
• Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by SurgeryTerminatedNCT00482625Phase 2Results posted
• Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT00481078Phase 2Results posted
• Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial CancerCompletedNCT00478426Phase 2Results posted
• Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by SurgeryTerminatedNCT00478140Phase 2Results posted
• Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT00475150Phase 2Results posted

← National Cancer Institute (NCI) overview and focus areas